A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of Daikenchuto (TU-100) in Subjects With Moderate Crohn's Disease
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72211
- Preferred Research Partners Inc
-
-
California
-
Corona, California, Forente stater, 92880
- TRIMED Clinical Trials
-
San Carlos, California, Forente stater, 94070
- Digestive Care Associates, LLC
-
San Francisco, California, Forente stater, 94115
- University of California at San Francisco
-
-
Colorado
-
Lakewood, Colorado, Forente stater, 80215
- Rocky Mountain Gastroenterology Associates
-
-
Florida
-
Clearwater, Florida, Forente stater, 22765
- Clinical Research of West Florida, Inc
-
Naples, Florida, Forente stater, 34102
- Gastroenterology Group of Naples
-
Winter Park, Florida, Forente stater, 32789
- Shafran Gastroenterology Center
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30542-5020
- Atlanta Gastroenterology Associates, LLC
-
Macon, Georgia, Forente stater, 31210
- Gastroenterology Associates of Central Georgia
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60637
- University of Chicago Hospital Medical Center
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40202
- University of Louisville School of Medicine
-
-
Maryland
-
Chevy Chase, Maryland, Forente stater, 20815
- Metropolitan Gastroenterology Group. PC
-
Towson, Maryland, Forente stater, 21204
- Endoscopic Microsurgery Associates PA
-
-
Massachusetts
-
Quincy, Massachusetts, Forente stater, 02169
- MedRACS
-
-
Michigan
-
Chesterfield, Michigan, Forente stater, 48047
- Clinical Research Institute of Michigan
-
Troy, Michigan, Forente stater, 48098
- Center for Digestive Health
-
-
Mississippi
-
Ocean Springs, Mississippi, Forente stater, 39564
- Digestive Health Center
-
-
Missouri
-
St. Louis, Missouri, Forente stater, 63128
- St. Louis Center for Clinical Research
-
-
New York
-
Great Neck, New York, Forente stater, 11021
- Long Island Clinical Research Associates, LLP
-
Hollis, New York, Forente stater, 11423
- NY Scientific CORP
-
-
North Carolina
-
Salisbury, North Carolina, Forente stater, 28144
- PMG Research of Salisbury
-
Winston-Salem, North Carolina, Forente stater, 27103
- PMG Research of Winston-Salem, LLC
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45219
- Consultants for Clinical Research
-
Cincinnati, Ohio, Forente stater, 45014
- Ohio Gastroenterology and Liver
-
-
Utah
-
Ogden, Utah, Forente stater, 84405
- Advanced Research Institute
-
-
Washington
-
Seattle, Washington, Forente stater, 98195
- University of Washington Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- provide written informed consent
- ability to orally ingest study medication
- male or female between 18 to 75 inclusive
- diagnosed with Crohn's disease for at least 3 months
- CDAI score of 220-300 at screening
- sexually active participants of childbearing potential must agree to birth control
- no clinically significant conditions which the doctor would feel exclusionary
- stable medication (including probiotics)
Exclusion Criteria:
- history of any bowel condition that may interfere with the evaluation of the study drug
- positive stool cultures
- currently pregnant or lactating
- receiving total parenteral nutrition
- history of alcohol or drug abuse within one year
- history of malignancy within 5 years
- current use of anticholinergic agents, antidepressants during the study, warfarin, prokinetics, antipsychotic agents or narcotic analgesics
- treatment with Anti-TNF agents 12 weeks before screening
- treatment with corticosteroids four weeks prior to screening
- treatment with cyclosporine or tacrolimus eight weeks prior to screening
- presence of a poorly controlled medical condition
- history of allergic reaction to ginseng, ginger or sichuan pepper
- any use of supplemental ginger, ginseng and Sichuan powder 2 weeks prior to and through course of the trial
- current use of any of the following herbal medications: Boswellia, Cat's claw (Uncaria tomentosa), Cayenne pepper, Echinacea, Horsetail (Equisetum), Hops, Lady's mantle (Alchemilla), Marshmallow root (Althaea), Slippery elm (Ulmus rubra) Turmeric and White Willow (Salix alba)
- history of celiac disease
- current diagnosis of lactose intolerance
- history of any other investigational medication within 30 days of enrolling in study
- unsuitability as determined by the study doctor
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: TU-100
15g TU-100 (oral, daily) for 8 consecutive weeks (administered as 5g three times daily)
|
15g daily, orally as 5g three times daily for 8 consecutive weeks
Andre navn:
|
|
Placebo komparator: Matching placebo
Matching placebo given 5g three times daily orally for 8 consecutive weeks
|
15g as 5g three times daily, orally for 8 consecutive weeks
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Clinical response as measured by a reduction in the CDAI total score
Tidsramme: over eight weeks
|
over eight weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
CDAI reduction by number of points and difference from baseline
Tidsramme: over eight weeks
|
over eight weeks
|
|
proportion of subjects showing a clinical remission by measure of CDAI score
Tidsramme: over eight weeks
|
over eight weeks
|
|
The change in total CDAI score
Tidsramme: every four weeks over eight weeks
|
every four weeks over eight weeks
|
|
The change in IBDQ total score and category sub-scores
Tidsramme: every four weeks over eight weeks
|
every four weeks over eight weeks
|
|
The change in CRP level
Tidsramme: every four weeks over eight weeks
|
every four weeks over eight weeks
|
|
The change in fecal calprotectin levels
Tidsramme: over eight weeks
|
over eight weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Etterforskere
Etterforskere
- Studieleder: Shunji Mochida, Ph.D., Tsumura USA
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- TU100P2T2
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .